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Background Existing scores to identify children at risk of hospitalized 
pneumonia-related mortality lack broad external validation. Our objective 
was to externally validate three such risk scores.
Methods We applied the Respiratory Index of Severity in Children (RISC) 
for HIV-negative children, the RISC-Malawi, and the Pneumonia Etiolo-
gy Research for Child Health (PERCH) scores to hospitalized children in 
the Pneumonia REsearch Partnerships to Assess WHO REcommendations 
(PREPARE) data set. The PREPARE data set includes pooled data from 41 
studies on pediatric pneumonia from across the world. We calculated test 
characteristics and the area under the curve (AUC) for each of these clin-
ical prediction rules.
Results The RISC score for HIV-negative children was applied to 3574 
children 0-24 months and demonstrated poor discriminatory abili-
ty (AUC = 0.66, 95% confidence interval (CI) = 0.58-0.73) in the identi-
fication of children at risk of hospitalized pneumonia-related mortality. 
The RISC-Malawi score had fair discriminatory value (AUC = 0.75, 95% 
CI = 0.74-0.77) among 17 864 children 2-59 months. The PERCH score 
was applied to 732 children 1-59 months and also demonstrated poor dis-
criminatory value (AUC = 0.55, 95% CI = 0.37-0.73).
Conclusions In a large external application of the RISC, RISC-Malawi, and 
PERCH scores, a substantial number of children were misclassified for their 
risk of hospitalized pneumonia-related mortality. Although pneumonia risk 
scores have performed well among the cohorts in which they were derived, 
their performance diminished when externally applied. A generalizable risk 
assessment tool with higher sensitivity and specificity to identify children 
at risk of hospitalized pneumonia-related mortality may be needed. Such 
a generalizable risk assessment tool would need context-specific validation 
prior to implementation in that setting.
Cite as: Rees CA, Hooli S, King C, McCollum ED, Colbourn T, Lufesi N, Mwansambo C, Lazzerini M, Madhi SA, Cutland C, Nunes 
M, Gessner BD, Basnet S, Kartasasmita CB, Mathew JL, Zaman SMA, Paranhos-Baccala G, Bhatnagar S, Wadhwa N, Lodha R, Aneja S, 
Santosham M, Picot VS, Sylla M, Awasthi S1, Bavdekar A, Jean-William Pape JW, Rouzier W, Chou M, Rakoto-Andrianarivelo M, Wang 
J, Nymadawa P, Vanhems P, Graiela Russomando G, Asghar R, Banajeh S, Iqbal I, MacLeod W, Maulen-Radovan I, Mino G, Saha S, Singhi 
S, Thea DM, Clara AW, Campbell H, Nair H, Falconer J, Williams LJ, Horne M, Strand T, Qazi SA, Nisar YB, Neuman MI; World Health 
Organization PREPARE study group. External validation of the RISC, RISC-Malawi, and PERCH clinical prediction rules to identify risk of 
death in children hospitalized with pneumonia. J Glob Health 2021;11:04062.
Worldwide, pneumonia is the most common cause of mortality among chil-
dren 1-59 months old [1,2]. Despite dramatic reductions in under-five mor-
tality rates during the Millennium Development Goal era, pneumonia caused 
more than 800 000 pediatric deaths as recently as 2017 [2,3]. Identification 
of children at risk of pneumonia-related mortality is the first step in directing 
supportive treatments, hospitalization, and oxygen support that have the po-
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count clinical data to predict an outcome, may aid in the distribution of resources to children at greatest risk 
of hospitalized pneumonia-related mortality.
To date, four clinical prediction rules have been derived to identify children at risk of hospitalized pneumo-
nia-related mortality [4-7]. The Respiratory Index of Severity in Children (RISC) score was developed retro-
spectively from >4000 hospitalized children aged 0-24 months old, with nearly 300 deaths, in South Africa in 
a 9-valent pneumococcal conjugate vaccine trial between 1998 and 2001 [4]. The RISC score stratified children 
who were human immunodeficiency virus (HIV)-positive and those who were HIV-negative. The Modified 
Respiratory Index of Severity in Children (mRISC) score was developed in >3500 hospitalized children aged 
0-59 months with >200 deaths in Kenya from 2009 to 2012 [5]. The third score, the RISC-Malawi score, was 
developed retrospectively using routinely collected clinical data from a cohort of >14 000 hospitalized chil-
dren 2-59 months old in Malawi, with more than 400 deaths from 2011 to 2014 [6]. Most recently, the Pneu-
monia Etiology Research for Child Health (PERCH) group derived a scoring system from 1800 HIV-negative 
children aged 1-59 months with 120 deaths from seven countries: Kenya, the Gambia, Mali, Zambia, South 
Africa, Thailand and Bangladesh [7]. The PERCH study aimed to determine the etiology of pneumonia among 
children presenting to hospitals in these regions from 2011-2014 [7].
These risk scores have not been widely validated using data from low- and middle-income settings outside 
sub-Saharan Africa [8,9]. The RISC score for HIV-negative children had fair discriminatory value when retro-
spectively applied to the PERCH and RISC-Malawi data sets, both of which were done after the pneumococcal 
vaccine became available and large scale prevention of mother to child transmission of HIV implementation 
[6,7]. The mRISC score, which used non-standard variables, to our knowledge has not been externally vali-
dated in any setting. In order for clinical prediction rules to be widely accepted and utilized, they must incor-
porate variables that can be feasibly collected in clinical practice.
Given the lack of published reports of their implementation, the impact of existing clinical prediction rules on 
reducing hospitalized pneumonia-related mortality is unclear [10]. Broad validation of existing clinical predic-
tion rules to identify children at risk of hospitalized pneumonia-related mortality in diverse settings is the first 
step towards wider clinical application of useful and robust clinical prediction rules. To this end, we aimed to 
externally validate existing clinical prediction rules for hospitalized pneumonia-related mortality in a diverse 
cohort of hospitalized children from the World Health Organization’s (WHO) Pneumonia REsearch Partner-
ship to Assess WHO REcommendations (PREPARE) study group.
METHODS
Study design
We applied the RISC, RISC-Malawi, and PERCH scores for hospitalized pneumonia-related mortality to all hos-
pitalized children with all included parameters in the WHO PREPARE study group data set. The mRISC score 
includes several variables (ie, history of night sweats, dehydration, history of decreased consciousness, and 
history of inability to drink or breastfeed) which were not widely available in the WHO PREPARE study group 
data set. Thus, similar to prior work attempting to externally validate the mRISC score [6], we did not include 
it in our analysis. We were also unable to externally apply the RISC score for HIV-positive children as it already 
been applied to 152 of the 159 children who had all reported parameters in the WHO PREPARE data set [6].
Ethical considerations
This study used de-identified individual patient data from previously published studies in which ethical ap-
proval was obtained at each participating site. Additional ethical approval was obtained by the WHO ethics 
review committee for one study sponsored by the WHO.
Data source
The WHO PREPARE data set has been described previously [11]. Briefly, this data set includes primary, pa-
tient-level data for children 0-59 months old evaluated for pneumonia. This is from 30 diverse study groups, 
comprising 41 separate data sets, from over 20 low- and middle-income countries in Asia, Africa, and Latin 
America as well as the United States of America and Australia. Data sets were identified from a systematic re-
view of childhood pneumonia [12]. Several additional data sets were included in PREPARE as the WHO was 
aware of ongoing and relevant studies. Investigators for these additional studies were invited to contribute to 
the PREPARE data set.
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Although some data sets included older children, the cohort was restricted to children 0-59 months of age to be 
consistent with most other pneumonia investigations in children [13-15]. We excluded community-based studies 
because our outcome was hospital based. We also excluded hospital-based studies that did not report survival data.
Pneumonia was defined in included studies included in the WHO PREPARE data set according to the WHO 
Pocket Book of Hospital Care for Children, based on the presence of age-adjusted tachypnea, lower chest in-
drawing, general danger signs (eg, abnormally sleepy, lethargy, central cyanosis, inability to drink, or convul-
sions), or signs of respiratory distress (eg, head nodding/bobbing, nasal flaring, or grunting) in children with 
a cough or difficulty breathing [16].
Variables
Our outcome measure was hospitalized pneumonia-related mortality during the respective study periods. Vari-
ables included in the RISC, RISC-Malawi, and PERCH scores are found in Table 1. The RISC score for HIV-neg-
ative children had a range of -2 to 6 points [4]. All variables included in the original RISC score for HIV-negative 
children were included in this external application. The RISC score assigned 3 points to HIV-negative children 
with SpO
2
≤90%. However, if a child’s SpO
2
 was >90%, chest indrawing became a part of the scoring system. 
If the SpO
2
 was ≤90%, chest indrawing was not included in the score assignment. Though originally derived 
among children 0-24 months old, we also applied the RISC score for HIV-negative children to children 0-59 
months old who had all necessary parameters available as a supplement.
Table 1. Summary of variables included in the Respiratory Index of Severity in Children (RISC) [4], RISC-Malawi [6], and 
Pneumonia Etiology Research for Child Health (PERCH) [7] hospitalized pneumonia-related mortality prediction scores
Parameter Weighted points Original derivation area under the curve







Refusal to feed 1
World Health Organization (WHO) weight for age z-score≤-3 2
WHO weight for age z-score>-3 to≤-2 1
Maximum score (original and external application) 6










WHO weight for age z-score≥-2 0
WHO weight for age z-score≥-3 to<-2 3





Maximum score (original and external application) 17
PERCH Study score for HIV-negative children 1-59 months
Age 1-11 months 2 0.76
Age 12-59 months 0
Male 0
Female 1
Unresponsive without deep breathing* 2






Maximum duration of illness 3-5 d 2
Maximum duration of illness >5 d 2
WHO weight for height z-score≥-2† 0
WHO weight for height z-score≥-3 to<-2 2
WHO weight for height z-score<-3 3
Maximum score (original) 17
Maximum score (external application) 12
*Deep breathing not available in WHO PREPARE data set.
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The RISC-Malawi score had a range of -1 to 17 using weight-for-age z-score (WAZ) and a range of -2 to 23 
points using mid-upper arm circumference (MUAC) [6]. As MUAC was only reported in two studies that met 
all inclusion criteria within the WHO PREPARE data set [17,18], we used the RISC-Malawi score with WAZ, 
applied to children aged 2-59 months, for our external application. The RISC-Malawi score using MUAC anal-
ysis is included as a supplement. The WHO PREPARE data set contains the RISC-Malawi development data 
set, and therefore these data were excluded from the external validation of the RISC-Malawi score [6].
The PERCH score had a range of -1 to 17 [7]. Its primary outcome was hospitalized pneumonia-related mortality 
or death within 7 days of hospital discharge. The PREPARE data set does not include the variable “deep breath-
ing”, which was included in the PERCH study, so this was not included in our analysis. Therefore, the maximum 
PERCH score in our external validation was 12 instead of 17. Furthermore, the PERCH score included the param-
eter of observed cough. For our external application, we included history of cough in place of observed cough. 
We used the variable unconsciousness in place of unresponsiveness as the definitions of both of these included 
descriptions such as unconsciousness, unresponsiveness, lethargy, and abnormally sleepy. In lieu of weight-for-
height, we used WAZ to measure children’s nutritional status as follows: weight-for-height z-score<-3 correspond-
ed to WAZ<-3 for severe acute malnutrition, weight-for-height z-score≥–3 to<–2 corresponded to WAZ of -3 to -2 
for moderate acute malnutrition, and weight-for-height z-score≥-2 corresponded to WAZ>-2 for normal weight.
Data analysis
We determined the accuracy of the RISC, RISC-Malawi, and PERCH scores on hospitalized children 0-59 
months old in the WHO PREPARE data set. We calculated the case fatality ratio (CFR), as the number of 
deaths/number of patients, and the percentage of patients who were correctly classified as true positive and 
true negative cases among all children at each cut point for each score. We calculated the sensitivity, speci-
ficity, and positive and negative likelihood ratios (LR) of each score at ≥ each specified cut point as defined in 
the scores. We created receiver operating characteristic (ROC) curves for each risk score. Based on published 
standards, we used the following scale to qualify the discriminatory ability of each score: area under the curve 
(AUC)≥0.90 for “excellent discrimination”, AUC 0.80 to 0.89 for “good discrimination”, AUC = 0.70-0.79 for 
“fair discrimination”, and “poor discrimination” for AUC<0.70 [19,20].
We conducted a complete case analysis and excluded cases with missing data for any parameter. In order to 
accurately identify children at low-risk of hospitalized pneumonia-related mortality, we aimed to report max-
imum sensitivity without sacrificing specificity. We, therefore, report risk score cut points with the sensitivity 
of 60%-80% with concurrent specificity of at least 40%. We present risk predictiveness curves, to show the 
cumulative percentage of children at risk of hospitalized pneumonia-related mortality by their predicted risk. 
We report test characteristics and 95% confidence intervals (CI) for the +LRs and the -LRs. All analyses were 
conducted using Stata version 14.2 (Stata-Corp, College Station, TX, USA).
RESULTS
Study population
Of the 41 separate data sets in the PREPARE study, there were 26 hospital-based studies and 15 communi-
ty-based studies (Figure 1). Of the 26 hospital-based studies in the WHO PREPARE data set, 24 studies in-
cluded data on patients’ survival status through hospitalization, with 228 460 patients aged 0-59 months old 
who were evaluated for pneumonia. Among these, there were 8820 (3.9%) hospitalized pneumonia-related 
deaths. We were able to apply the RISC score for HIV-negative children 0-24 months old to 3574 children 
from five studies [6,17,18,21,22], the RISC-Malawi score to 17 864 children 2-59 months old from 10 studies 
[17,18,21-28], and the PERCH score to 732 children 1-59 months old from two studies [17,21] (Figure 1). 
A total of 732 children had data available for all three scores [17,21]. Characteristics of individual included 
studies are found in Table 2. The CFR in the included studies ranged from 0.9%-10.9%.
RISC score for HIV-negative children
The numbers of patients who had each parameter of the RISC score for HIV-negative children with correspond-
ing CFRs are found in Table 3. Of the parameters in the RISC score for HIV-negative children 0-24 months 
old, children who refused to feed at presentation had the highest CFR and children who had presented with 
wheeze had the lowest CFR. The RISC score for HIV-negative children 0-24 months old had poor discrimina-
tory ability in identifying children at risk of hospitalized pneumonia-related mortality (Figure 2). The CFR at 
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a RISC score of 2 out of 6 for HIV-negative children 0-24 months old was 0.8%. Using a score of ≥2, the RISC 
score for HIV-negative children 0-24 months old had 74.1% sensitivity, 41.4% specificity, +LR of 1.26 (95% 
CI 1.05-1.44), and -LR of 0.64 (95% CI 0.45-1.01) (Table S1 in the Online Supplementary Document). The 
RISC score for HIV-negative children performed similarly when applied to 4061 children aged 0-59 months 
with a score of 2 out of 6 (Table S2 and Table S3 in the Online Supplementary Document).
RISC-Malawi Score
We applied the RISC-Malawi score using WAZ to 17 864 children 2-59 months old in the WHO PREPARE data 
set. Of the parameters in the RISC-Malawi score, patients who had documented unconsciousness at presenta-
tion had the highest CFR, and children with SpO
2
≥93% had the lowest CFR (Table 4). The RISC-Malawi score 
had fair discriminatory value in the identification of children at risk of hospitalized pneumonia-related mortality 
(Figure 2). At a score of ≥5 out of 17, the RISC-Malawi score had 75.1% sensitivity, 67.9% specificity, +LR of 
2.27 (95% CI = 2.17-2.37), and -LR of 0.37 (95% CI = 0.33-0.42) in identifying children at risk of hospitalized 
pneumonia-related mortality (Table S4 in the Online Supplementary Document). Using a cut-point score of 
≥6 out of 17, the RISC-Malawi score using WAZ had 61.6% sensitivity, 75.5% specificity, +LR of 2.51 (95% 
CI = 2.37-2.66), and -LR of 0.51 (95% CI = 0.47-0.55) (Table S4 in the Online Supplementary Document).
When applying the RISC-Malawi MUAC score to 2251 patients, the parameter SpO
2
<90% demonstrated the 
highest CFR (Table S5 in the Online Supplementary Document). Though the +LR and -LR were slightly 
lower with MUAC included instead of WAZ, overall the RISC-Malawi score performed similarly with MUAC 
included as the parameter for malnutrition (Table S6 in the Online Supplementary Document).
Figure 1. Selection of children aged 0-59 months from hospital-based studies included in the external application of the Re-
spiratory Index of Severity in Children (RISC), RISC-Malawi, and Pneumonia Etiology Research for Child Health (PERCH) 
scores. aThe sum of patients included in the 4 individual validation cohorts does not total 41 365 as the validation each 
of the 4 scores required that every component of the score be available within the data set. bExcluding the parent data set 
from which the RISC-Malawi score was derived. cExcluding 610 children less than 2 months of age. dExcluding 105 chil-
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Table 2. Characteristics of studies included in the Pneumonia REsearch Partnerships to Assess WHO REcommendations (PREPARE) data set





Inclusion and exclusion 
criteria Score(s) applied (n)
Hooli 2016 
[6]




0-59 16 475 524 
(3.2)
Inclusion: children with World 
Health Organization (WHO)-de-
fined pneumonia* of any severity
Respiratory Index of Se-




Chandigarh, India Prospective 
cohort
1-59 2400 157 
(6.5)
Inclusion: children with WHO-de-








Phnom Penh, Cambodia Prospective, case-
control study
2-59 888 20 (2.2) Inclusion for cases: Children with 
WHO-defined pneumonia with first 
symptoms lasting <14 days
RISC HIV-negative (445)
Beijing, China





Banako, Mali Radiographic confirmation of pneu-
monia (WHO criteria)
Ulaanbaatar, Mongolia No wheezing
San Lorenzo, Paraguay Inclusion for controls: no symptoms 
suggestive of respiratory illness, out-




Kathmandu, Nepal Randomized 
controlled trial
2-35 641 6 (0.9) Inclusion: children with a complaint 
of cough for <14 days, complaint of 
difficulty breathing for ≤72 h, pres-
ence of lower chest wall indrawing, 
or presence of lower chest indraw-
ing on examination by study physi-








0-59 85 2 (2.3) Inclusion: children with severe 








0-23 6221 676 
(10.9)









0-59 10 114 452 
(4.5)
Inclusion: based on International 





Dhaka, Bangladesh Randomized 
controlled trial
2-59 958 46 (4.8) Inclusion: children with WHO-de-










New Delhi, India Randomized 
controlled trial
2-24 550 8 (1.5) Severe pneumonia: fast breathing: 
≥50 breaths/min in children 2-11 




Presence of chest indrawing
Very severe pneumonia: severe 
pneumonia (with or without chest 
indrawing) and any general danger 
sign (ie, lethargy or inability to drink 
or convulsions) or central cyanosis
Cutts 2005. 
[27]
Upper River and 




1-30 1716 106 
(6.2)
Inclusion: history of cough or diffi-
cult breathing with an elevated re-
spiratory rate for age (≥50 breaths 
per min for children <1 year old and 
≥40 per min for children ≥1 year 




West Java, Indonesia Retrospective 
cohort
0-59 1317 69 (5.2) Inclusion: children with WHO-de-
fined pneumonia
RISC-Malawi (830)
*WHO-defined pneumonia: presence of age-specific fast breathing, lower chest indrawing, or general danger signs in children with a cough or difficulty
†Cough and/or difficulty breathing, and central cyanosis or inability to drink.










www.jogh.org • doi: 10.7189/jogh.11.04062 7 2021  •  Vol. 11  •  04062
PERCH score for HIV-negative children
We applied the PERCH score to 732 children 1-59 months old in the WHO PREPARE data set. Of the pa-
rameters included in the PERCH score, patients who had WAZ<-3 had the highest CFR. Children with unre-
sponsiveness had the lowest CFR (Table 5). The PERCH score had poor discriminatory value in identifying 
children at risk of hospitalized pneumonia-related mortality (Figure 2). The CFR at a PERCH score of 5 was 
0.6%. A PERCH score of ≥5 had 62.5% sensitivity, 29.6% specificity, +LR of 0.89 (95% CI = 0.61-1.30), and 
-LR of 1.27 (95% CI = 0.67-2.41) (Table S7 in the Online Supplementary Document).
Risk predictiveness curves
Risk predictiveness curves demonstrated that the majority of children were low risk for mortality (Figure 3).
DISCUSSION
Clinical prediction rules previously derived among children in sub-Saharan Africa, Thailand, and Bangla-
desh performed sub-optimally in identifying hospitalized pneumonia-related mortality when externally 
applied to a diverse population of children from 19 countries. Both the RISC score for HIV-negative chil-
dren and the PERCH score had poor discriminatory value when externally applied to the PREPARE data 
set, and the RISC-Malawi score had fair discriminatory value in identifying children at risk of hospitalized 
pneumonia-related mortality.
Among HIV-negative children, we observed that the RISC score had poor discriminatory value in identify-
ing children at risk of hospitalized pneumonia-related mortality in both children 0-24 and 0-59 months old. 
This is in contrast to the external application of the RISC score for HIV-negative among >14 000 children in 
Malawi and the external application in the PERCH data set including >1800 children from seven countries in 
which RISC score had fair discriminatory value among all children and among HIV-exposed children [6,7]. 
The poor performance of the RISC score in our external application may be due to having more diverse pa-
tient populations, including differing rates and types of comorbidities among children outside sub-Saharan 
Table 3. Number of patients, deaths, and case fatality ratio of parameters used in the Respiratory Index of Severity in Children (RISC) score 
for HIV-negative children 0-24 mo old in the Pneumonia REsearch Partnerships to Assess WHO REcommendations (PREPARE) data set 
(n = 3574)
Parameter Sign or symptom  present, n (%) Deaths, n
Case fatality ratio % 
 (95% confidence interval)
Oxygen saturation (SpO
2
)≤90% 917 (25.6) 20 2.2 (1.3-3.3)
Chest indrawing (with SpO
2
>90%) 2358 (66.0) 27 1.1 (0.7-1.7)
Wheezing 1487 (41.6) 15 1.0 (0.6-1.7)
Refusal to feed 351 (9.8) 16 4.6 (2.6-7.3)
World Health Organiztion (WHO) weight for age z-score≤-3 285 (8.0) 10 3.5 (1.7-6.3)
WHO weight for age z-score -2≤z<-3 435 (12.2) 13 3.0 (1.6-5.0)
Total 61 1.7 (1.3-2.2)
Table 4. Number of patients, deaths, and case fatality ratio for parameters in the Respiratory Index of Severity in Children 
(RISC)-Malawi score using weight-for-age z-score (WAZ) for children 2-59 mo old in the PREPARE data set (n = 17 864)






≥93% 9804 (54.9) 243 2.5 (2.2-2.8)
SpO
2
 90%-92% 3727 (21.9) 118 3.2 (2.6-3.8)
SpO
2
<90% 4333 (24.2) 508 11.7 (10.8-12.7)
World Health Organization (WHO) weight-for-age z score (WAZ) categories:
WAZ>-2 11 973 (67.0) 395 3.3 (3.0-3.6)
WAZ -2 to -3 3157 (17.7) 212 6.7 (5.9-7.6)
AZ<-3 2734 (15.3) 262 9.6 (8.5-10.7)
Female 8360 (46.8) 466 5.6 (5.1-6.1)
Wheezing 5489 (30.7) 174 3.2 (2.7-3.7)
Unconscious/decreased consciousness 738 (4.1) 96 13.0 (10.7-15.6)
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Africa. Although 68% of patients included in our external 
application were located in sub-Saharan Africa, these stud-
ies generally have lower childhood mortality rates than the 
original patient group. Given the challenges we found in 
accessing reliable routine data on HIV-status in children, 
changes in HIV prevention and management in sub-Saha-
ran Africa [29], and assumed changes in underlying pneu-
monia etiology since widespread pneumococcal vaccine in-
troduction [30], poor to fair external performance was not 
necessarily surprising.
Though the PERCH score derivation included multiple 
countries, unlike the other scores evaluated, it had the 
poorest discriminatory value in identifying children at risk 
of hospitalized pneumonia-related mortality. This may be 
partly explained by our inability to include the variable 
“deep breathing” or the substitution of WAZ in place of 
weight-for-height z-score. Deep breathing is not a standard 
variable in the WHO screening for pneumonia. Similar to 
the mRISC score, which has not been externally validated, 
this highlights the challenge of including variables that are 
not included in routine guidelines in practical clinical pre-
diction rules. While such inclusion may improve local per-
formance, their ability to be pragmatically scaled or validat-
ed may be limited. Furthermore, our substitution of WAZ 
for weight-for-height z-score may also limit the external val-
idation of the PERCH score as weight-for-height z-score may 
more accurately account for both present and past nutrition-
al status [31]. Further validation studies using the precise 
variables included in the PERCH score across a variety of 
settings are warranted.
Figure 2. Receiver Operating Characteristic (ROC) curve for the Respi-
ratory Index of Severity in Children (RISC) score for HIV-negative chil-
dren 0-24 months old, RISC-Malawi weight-for-age (WAZ) score for 
children 2-59 months old, and Pneumonia Etiology Research for Child 
Health (PERCH) score for HIV-negative children 1-59 months old for 
hospitalized pneumonia-related mortality.
Table 5. Number of patients, deaths, and case fatality ratio by parameter used in the Pneumonia Etiology Research for Child Health 
(PERCH) study score for HIV-negative children 1-59 mo old in the Pneumonia REsearch Partnerships to Assess WHO REcommendations 
(PREPARE) data set (n = 732)
Parameter Sign or symptom present, n (%) Deaths, n Case fatality ratio %  (95% confidence interval)
Age 1-11 months 569 (77.7) 13 2.3 (1.2-3.9)
Female 277 (37.8) 7 2.5 (1.0-5.1)
Unresponsiveness 102 (13.9) 0 0.0 (-)
Cough – (history) 731 (99.9) 16 2.2 (1.3-3.5)
Grunting – (observed) 137 (18.7) 5 3.7 (1.2-8.3)
Oxygen saturation (SpO
2
)<92% 526 (71.9) 9 1.7 (0.8-3.2)
Maximum duration of illness – 3 d or more 633 (86.5) 15 2.4 (1.3-3.9)
World Health Organization (WHO) weight-for-age z-score<-3 83 (11.3) 6 7.2 (2.7-15.1)
WHO weight-for-age z-score≥-3 to<-2 120 (16.4) 1 0.8 (0.01-4.6)
Total 16 2.2 (1.2-3.5)
Among the clinical prediction rules externally applied in our study, the RISC-Malawi score had the most 
discriminatory value. However, the AUC for the RISC-Malawi score demonstrated only fair discriminato-
ry value. The improved performance of the RISC-Malawi score may be due to fewer physical examination 
findings included as parameters in this score. Variation in inter-observer agreement of physical examina-
tion findings could lead to classification errors that would ultimately under-estimate the effect of a clinical 
prediction tool [32,33]. Moreover, malaria and HIV, though endemic in Malawi, were not incorporated into 
the score due to underreporting of these variables [6]. As HIV and malaria are common in Malawi among 
children [34,35], it is possible that the exclusion of these variables may have driven mortality risk as an un-
measured confounding parameter. Lastly, we were able to apply the RISC-Malawi score to over 17 000 chil-
dren, which suggests it may be the clinical prediction rule that allows for widest dissemination based on 
the use of data routinely collected in clinical practice across a variety of settings.
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Although clinical prediction rules tend to underperform when applied externally to populations in which they 
were derived, none of the clinical prediction rules externally applied here demonstrated excellent discrimi-
natory value. Thus, clinical prediction rules for hospitalized pneumonia-related mortality may not be confi-
dently applied in settings beyond where they were derived. Some of the underperformance of these clinical 
prediction rules in our external validation may be due to varying resources such as high-flow nasal cannula, 
non-invasive ventilation, or mechanical ventilation and perhaps limited oxygen and pulse oximetry in some 
settings included in the WHO PREPARE data set. Furthermore, variations in quality of care, diagnostic capa-
bilities, region-specific pathogens implicated in childhood pneumonia, and antibiotic use across the 19 coun-
tries included in our analysis may have contributed to the underperformance of these clinical prediction rules.
Age <12 months, chest indrawing, grunting, respiratory rate >70 breaths/min, hepatomegaly, acute moderate 
and severe malnutrition, and the presence of moderate or severe pallor have been shown to be independently 
associated with pneumonia-related mortality among children and may be candidate predictors in future risk 
assessment tools [36,37]. Both the RISC and RISC-Malawi scores demonstrated that the presence of wheezing 
was associated with lower mortality rates among children, likely suggestive of the presence of a viral etiology, 
such as bronchiolitis [38]. Moreover, serum lactate and biomarkers such as C-reactive protein and procalcitonin 
may be associated with severe outcomes in childhood pneumonia [39-42] and may be considered for imple-
mentation in future mortality risk assessment tools in settings where these tests are available. However, such 
biomarkers may not be widely available, could prove cost prohibitive, and involve mildly invasive blood draws.
Limitations
Though this is the first broad external validation outside of sub-Saharan Africa of the RISC, RISC-Malawi, and 
PERCH scores, our analysis is subject to limitations. First, the PREPARE data set includes data from studies 
around the world that were conducted for varying reasons and not necessarily for the external application 
of these hospitalized pneumonia-related mortality clinical prediction rules. This led to missing variables for 
many children which precluded our ability to include children with missing data in our external application 
of these risk scores. As a result, the ROC curves for each score were applied to different patient populations 
with varying sample sizes. We were not able to apply the RISC score for HIV-positive children to this diverse 
data set due to lack of reporting of HIV status. This may be an artifact of the enrollment protocols of the stud-
ies included in our data set. A large proportion of patients included in our external application of these scores 
were from Malawi and South Africa, which may have over- or under-estimated the performance of these scores 
in settings outside of sub-Saharan Africa. Furthermore, we did not control for patient skin color or altitude, 
which may affect the accuracy of pulse oximetry [43-45].
In terms of the PERCH score, we were unable to externally validate this tool as its developers intended be-
cause the WHO PREPARE data set did not include a variable for deep breathing, which may have led to some 
mis-calibration of our external application of the PERCH risk score. Furthermore, we were only able to apply 
the PERCH score to 732 children who had complete data for the variables included. Additionally, we only an-
alyzed hospitalized pneumonia-related mortality as post-discharge mortality was not available in the PREPARE 
data set and the PERCH score predicts hospital and up to 7-day post-discharge mortality. However, post-dis-
Figure 3. Risk predictiveness curves of the Respiratory Index of Severity in Children (RISC) score for HIV-negative children 0-24 months 
old (A), RISC-Malawi weight-for-age (WAZ) score for children 2-59 months old (B), and Pneumonia Etiology Research for Child Health 
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